There’s big volatility ahead for this sector: Goldman Sachs

The market in autumn tends to see an uptick in volatility — and Goldman Sachs forecasts the health-care sector could see a particularly rocky upcoming month.

The investment bank's options research team, in a note published last week, said it is focused particularly on option buying strategies to "capitalize on the seasonal pick up in health care [volatility] during this election year."

Volatility tends to rise in October for the broader market, the note's authors acknowledged.

But other catalysts could lend themselves to further turbulence for health care in particular, citing "key" health-care and biotech conferences, analyst meetings, earnings season and the presidential debates.

"Clearly, the election is a big deal, but recent price moves have indicated a huge public dissatisfaction with pharmaceutical prices," Max Wolff, chief economist at Manhattan Venture Partners, said Friday on "Trading Nation."

In the first 100 days of a presidency — often considered a defining period of time for a new public official — big changes could come to the infrastructure of the health-care sector, which could likely affect the pricing power of health-care companies.

Issues around sudden increases in health-care costs have come to the fore, most recently related to pharmaceutical company Mylan coming under fire for its EpiPen price increases.

"It's a very solid idea," Nicholas Colas, chief market strategist at Convergex, said Friday on "Trading Nation," referring to the bank's call.

Right now, the CBOE Volatility Index is around 12, noted Colas. Around last October, the "fear gauge" was at about 30.

The S&P health-care sector ETF, the XLV, is down about 2 percent this month.

"So volatility could more than double, and still be within the norms of the move from September to October volatility."

The note's authors recommend, among other names, buying October 16 calls of biopharmaceutical company Alkermes.

Goldman Sachs analysts forecast the company's Vivitrol drug, prescribed to treat opioid addiction, will receive a greater-than-expected total addressable market from Alkermes management.

Wolff, of Manhattan Venture Partners, said the volatility index is not telling the whole story at this point.

"Certainly, the volatility suggests a very calm, still situation, when the election and the general public debates suggest the opposite," he said Friday.


Trades to Watch

Trader Bios


Trading Nation is a multimedia financial news program that shows investors and traders how to use the news of the day to their advantage. This is where experts from across the financial world – including macro strategists, technical analysts, stock-pickers, and traders who specialize in options, currencies, and fixed income – come together to find the best ways to capitalize on recent developments in the market. Trading Nation: Where headlines become opportunities.

Michael Santoli

Michael Santoli joined CNBC in October 2015 as a Senior Markets Commentator, based at the network's Global Headquarters in Englewood Cliffs, N.J.  Santoli brings his extensive markets expertise to CNBC's Business Day programming, with a regular appearance on CNBC's Closing Bell (M-F, 3PM-5PM ET). In addition, he contributes to CNBC and CNBC PRO, writing regular articles and creating original digital videos.

Previously, Santoli was a Senior Columnist at Yahoo Finance, where he wrote analysis and commentary on the stock market, corporate news and the economy. He also appeared on Yahoo Finance video programs, where he offered insights on the most important business stories of the day, and was a regular contributor to CNBC and other networks.

Follow Michael Santoli on Twitter @michaelsantoli

Read more